---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038015"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:08:49.337875+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# KalVista Q3 fiscal 2025: $253.2M cash, sebetralstat regulatory progress; PDUFA June 17

## Summary
- No revenue; R&D expense $12.6M (down from $22.5M YoY); G&A $30.3M (up from $10.6M) due to pre-commercial activities.
- Cash, cash equivalents and marketable securities of $253.2M as of Jan 31, 2025.
- Sebetralstat NDA submitted in Japan, orphan drug designation granted; U.S. PDUFA date June 17, 2025.
- Raised $160M gross proceeds in Nov 2024 via synthetic royalty financing and equity offerings to fund launch.
- Field sales team onboarded; Jeb Ledell appointed COO; new data presented on laryngeal attacks, adolescents, and LTP patients.

## SEC filing metadata
- accession: 0000950170-25-038015
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017025038015/0000950170-25-038015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017025038015/kalv-20250312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038015
- JSON: https://secwatch.observer/filing/0000950170-25-038015.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.